Primary Prevention of Atherosclerotic Cardiovascular Disease
Cardiovascular·MeSH: Cardiovascular Diseases
Prevalence
6000.0 / 100K
Incidence
500.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| inclisiran sodium 300 mg in | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Primary Prevention of Atherosclerotic Cardiovascular Disease?
BioSniper tracks 1 drug in development for Primary Prevention of Atherosclerotic Cardiovascular Disease across 1 company.
How many clinical trials target Primary Prevention of Atherosclerotic Cardiovascular Disease?
There are 1 clinical trial targeting Primary Prevention of Atherosclerotic Cardiovascular Disease tracked by BioSniper.
What is the prevalence of Primary Prevention of Atherosclerotic Cardiovascular Disease?
The estimated prevalence of Primary Prevention of Atherosclerotic Cardiovascular Disease is approximately 6000.0 per 100,000 population.
Deep-dive into Primary Prevention of Atherosclerotic Cardiovascular Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis